Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
Follow-Up Questions
Treace Medical Concepts Inc 的 CEO 是谁?
Mr. John Treace 是 Treace Medical Concepts Inc 的 Chairman of the Board,自 2014 加入公司。
TMCI 股票的价格表现如何?
TMCI 的当前价格为 $6.44,在上个交易日 decreased 了 0%。
Treace Medical Concepts Inc 的主要业务主题或行业是什么?
Treace Medical Concepts Inc 属于 Health Care 行业,该板块是 Health Care